Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be able to access treatment with Alnylam's gene-silencing drug Amvuttra. The ruling by reimbursement ...

The European Commission has approved BridgeBio's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market clash with Pfizer. The oral drug ...

The roof is one of the most expensive components of a commercial or industrial property. It protects everything inside yet, ...

Visitors to your website might want directions to your store via Google Maps, a roundup of your social media feeds, and a ...

Preliminary unaudited Q4 and Full Year 2025 net Attruby®product revenue of $146.0 million and $362.4 million, respectively ...

ARKF offers thematic returns through growth stock exposure, benefiting from pro-risk environments and tech rallies. See why ...

Avoid these mistakes to build automation that survives UI changes, validates outcomes properly, and provides useful feedback.

If you’ve been watching your analytics lately, you might have noticed a confusing trend: organic search numbers are dipping, ...

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.

The successful commercialization of Attruby could establish BridgeBio as a key player in the ATTR-CM market, significantly improving its path to profitability.

Group calls for review of retailer’s partnership with Flock Safety, whose data has been used in ​immigration enforcement ...

A. A mark is a given and known sign by which a thing can be distinguished from all others of its kind. Thus a trademark is used to distinguish the article bearing it from all imitations of the same ...